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Abstract 
Treatment with several antiepileptic drugs (AED) is associated with lower serum 
concentrations of folate or vitamin B12. Several small studies suggest that AED treatment 
may also interfere with vitamin B6 plasma levels. This prospective monocenter study 
analyzed vitamin B6 blood levels in 400 serial patients with epilepsy, AED-treated (n = 385) 
or untreated (n = 15).  As healthy local controls, 233 age- and gender-matched blood donors 
were analyzed. Individuals supplementing vitamin B6 were not eligible.  
The mean plasma vitamin B6 levels (µg/ml ± 1 standard deviation, SD) of the AED-treated 
(12.1 ± 10.1; F = 2.84; p = 0.093) and the untreated patients (15.6 ± 12.4; F = 0.19; p = 0.664) 
were not significantly different from the controls (13.9 ± 15.2) tested by ANOVA. 
Accordingly, the frequency of vitamin B6 plasma levels below the reference range (5 µg/ml) 
of the AED-treated (0.12; Chi = 0.02; p = 0.882) and the untreated patients (0.13; Chi = 0.01; 
p = 0.959) did not significantly differ from the controls (0.13; Pearson’s Chi2). Explorative 
subgroup analysis did not reveal that single AED were associated with vitamin B6 mean 
plasma levels or levels below the reference range both in poly- or monotherapies. In patients 
with vitamin B6 plasma levels below the reference range, oral substitution with 20 mg per day 
lead to reconstitution of the plasma levels. These observations do not support the hypothesis 
that vitamin B6 blood levels are influenced by AED treatment.  
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Objective 
Treatment with several of the commonly used antiepileptic drugs (AED) is associated with 
lower folate or vitamin B12 serum levels (Linnebank, et al. 2011). Although reports have 
remained controversial, several studies have also suggested decreased vitamin B6 plasma 
levels in association with treatment with carbamazepine n = 20 patients (Attilakos, et al. 
2006), n = 19 (Sener, et al. 2006), n = 28 (Verrotti, et al. 2000), n = 20 (Tamura, et al. 2000), 
phenytoin n = 20 (Tamura, et al. 2000), valproate n = 13 (Tamura, et al. 2000), n = 32 
(Verrotti, et al. 2000) or with any AED treatment n = 101 (Apeland, et al. 2003), n = 500 
(Krause, et al. 1988), n = 51 (Schwaninger, et al. 1999), n = 59 (Vilaseca, et al. 2000). Major 
et al. suggested that substitution of vitamin B6 lowered behavioral side effects of 
levetiracetam in 42 pediatric patients (Major, et al. 2008). 
Vitamin B6, in its active form, is necessary for numerous amino acid transformation 
reactions. In the brain, the synthetic pathways for dopamine, noradrenaline and 5-
hydroxytryptamine contain enzymes that require vitamin B6 for their function. Further, both 
glutamate decarboxylase and -aminobutyrate (GABA) aminotransferase, the enzymes of 
GABA synthesis and degradation, employ vitamin B6 for their catalytic mechanisms 
(Tunnicliff 1986, Tunnicliff, et al. 1986). 
In summary, AED treatment may compromise vitamin B6 plasma levels and thereby different 
pathways of human metabolism, e.g. neurotransmitter synthesis and degeneration. However, 
the available epidemiological studies are small or analyzed only older AED. In the present 
study, plasma vitamin B6 levels were analyzed in 400 patients with epilepsy and in 233 
healthy controls.  
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Methods 
This prospective study included serial in- and out-patients of the Department for Epileptology 
of the University Hospital Bonn, Germany, who suffered from epilepsy. Period of recruitment 
was November and December 2006. Patients with epilepsy treated with the therapy when 
presenting at our hospital for at least three months were enrolled as AED-treated patients (n = 
385, mean age (y) ± 1 standard deviation (SD) = 38 ± 14; ratio female: 0.49). Patients not 
treated with any AED for at least three months were enrolled as untreated patients (n = 15; 40 
± 19 y; 0.47 female). Patients were not eligible if they supplemented vitamin B6. Age- and 
gender-matched, but otherwise unselected 233 blood donors served as healthy local controls 
(n = 233; 37 ± 15 y; 0.48 female). The study was approved by the local ethics committee. 
Vitamin B6 was measured in plasma in the clinical routine. SPSS version 16 was used for 
statistical analysis (SPSS, Chicago, IL, USA). Pearson’s Chi2 tests and univariate analysis of 
variance (ANOVA) were used for univariate analysis of numeric and metric data, 
respectively. For the analysis of associations with single AED and vitamin B6, only AED 
taken by at least 20 patients were analyzed. In total, 177 of the 385 patients (46%) were 
treated with monotherapies.  
 
 5
Results and discussion 
None of the analyzed AED was associated with mean vitamin B6 plasma levels or with the 
frequency of vitamin B6 plasma levels below the reference range. Accordingly, untreated 
patients showed no differences compared with treated patients (table 1). Results did not differ 
if only patients treated with AED monotherapy were analyzed (not shown). In total, 48 (12%) 
of the patients had vitamin B6 plasma levels below the reference range. None of these 
individuals was pregnant. All were offered to supplement vitamin B6. Because of the 
unknown biological relevance of vitamin B6 levels below the laboratory reference range, only 
32 patients decided to start therapy. Initially, we advised 100 mg per os per day as approved 
for oral therapy of vitamin B6 deficiency, but three patients claimed newly evolved 
disturbances of sensibility compatible with peripheral sensory neuropathy as known as 
possible side effect of vitamin B6. Therefore, we only substituted 20mg thereafter. With this 
regimen, vitamin B6 plasma levels became reconstituted in all individuals, and no signs of 
neuropathy were reported or detected in follow-up examinations. Although not studied in a 
standardized manner, we did not observe any improvement, nor deterioration, of seizure 
frequency or neurological findings related to vitamin B6 substitution in follow-up 
examinations. These observations do not support the hypothesis that vitamin B6 blood levels 
are influenced by AED treatment. Consequently, the present study does not suggest that 
vitamin B6 blood levels should be monitored in patients treated with AED or that this vitamin 
should prophylactically substituted in respective individuals. Thirteen percent of the healthy 
controls and 12% of the patients had vitamin B6 blood levels below the reference questioning 
the accuracy of the applied reference range. Larger studies should be performed to generate 
valid reference data. If vitamin B6 is to be substituted, 20mg/ day per os may be chosen, 
which has been safe and sufficient in our study.   
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Table 1: Vitamin B6 plasma levels 
 
Mean plasma levels 
(µg/ml) ± SD 
vs healthy controls  
Frequency of 
subnormal levels 
vs healthy controls  
Healthy controls (n=233) 13.9 ± 15.2 -- 0.13 -- 
All AED-treated patients (n=385) 12.1 ± 10.1 F = 2.84; p = 0.093 0.12 Chi = 0.02; p = 0.882 
Untreated patients (n=15) 15.6 ± 12.4 F = 0.19; p = 0.664 0.13 Ch = 0.01; p = 0.959 
Clobazam (n=33) 12.1 ± 10.2 F = 0.41; p = 0.525 0.15 Chi = 0.13; p = 0.717 
Carbamazepine (n=80) 14.9 ± 15.6 F = 0.28; p= 0.595 0.15 Chi = 0.23; p = 0.631 
Lamotrigine (n=125) 12.2 ± 8.8 F = 1.22; p = 0.271 0.15 Chi = 0.372; p = 0.324 
Levetiracetam (n=120) 11.1 ± 7.9 F = 3.55; p = 0.060 0.13 Chi = 0.10; p = 0.920 
Oxcarbazepine (n=49) 11.1 ± 8.9 F = 1.49; p = 0.223 0.16 Chi = 0.41; p = 0.520 
Phenobarbital (n=32) 11.3 ± 7.8 F = 0.86; p = 0.355 0.16 Chi = 0.19; p = 0.667 
Phenytoin (n=25) 8.7 ± 4.0 F = 2.81; p = 0.095 0.20 Chi = 0.98; p = 0.323 
Pregabalin (n=39) 10.8 ± 6.6 F = 1.57; p = 0.211 0.10 Chi = 0.21; p = 0.647 
Topiramate (n=36) 11.1 ± 8.9 F = 1.13; p = 0.289 0.14 Chi = 0.03; p = 0.866 
Valproate (n=103) 10.9 ± 7.9 F = 3.46; p = 0.064 0.15 Chi = 0.18; p = 0.675 
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